CommercialCoverageHigh impact
Autologous Chondrocyte Implantation (ACI) 7.01.38
Excellus BlueCross BlueShield·Orthopedics, Sports Medicine·Bone & Joints (Orthopedic)
Effective date
Oct 15, 2025
We identified it
Jul 16, 2026
Summary
Excellus BlueCross BlueShield established a new medical policy (7.01.38) effective October 15, 2025, for Autologous Chondrocyte Implantation (ACI) using matrix-induced ACI (MACI) implants for knee cartilage defects. The policy defines strict coverage criteria including BMI ≤35, age 15-55, specific imaging/arthroscopic findings, and failure of conservative management for ≥3 months. Hybrid ACI/OATS procedures are classified as investigational and not covered. This is a brand-new policy requiring immediate billing system updates and prior authorization protocols.
Action Required
By October 15, 2025: Billing team must implement prior authorization requirements for ACI/MACI procedures in the billing system. Create a coverage criteria checklist verifying: BMI ≤35, patient age 15-55, Kellgren-Lawrence Grade II or less, full-thickness defect 1-10cm², at least 3 months of failed conservative management, stable knee with intact ligaments, and normal alignment. Providers must document all criteria in clinical notes before claims submission. Flag claims for Hybrid ACI/OATS as investigational/non-covered and deny. Update encounter templates and superbills to remind providers of coverage requirements. Train front desk and billing staff on the 6-month surgery exclusion window and contraindications (hypersensitivity to gentamicin/porcine/bovine products, coagulation disorders, ligament instability, recent meniscectomy >50%, septic arthritis within 1 year). Non-compliant claims will be denied.